Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

February 24, 2022

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 69 min

Earnings Call Speaker Segments

Lawrence Keusch

executive
#1

Hello, everyone, and good morning. Thank you for joining us for the Teleflex Incorporated Q4 2021 earnings conference call. You can find the press release and the slides that go with this call on our website, teleflex.com. Just a reminder that this call is being webcast on our site, and a replay can be accessed by calling 800 to 585 to 8367, or if you're calling internationally, 416 to 621 to 4642, and the passcode is 1028958. On the call with us today are Liam Kelly, our Chairman, President, and Chief Executive Officer, and Thomas Powell, our Executive Vice President and Chief Financial Officer. Liam and Tom are going to give prepared remarks, and after that, we'll open things up for Q&A. Before we get started, I want to remind everyone that a number of the topics we'll discuss on this conference call will include forward-looking statements about future events, as described in our slides. We want to caution you that these statements are indeed forward-looking in nature and are subject to risks and uncertainties, and that actual events or results could differ materially. Among the factors that could lead actual results or events to differ materially are those referenced in our press release issued today, as well as in our filings with the SEC, including our Form 10-K, which you can access on our website. During this conference call, you'll hear management discuss intra-quarter business performance. Management is offering this commentary to give the investment community additional insights into trends, and these disclosures might not be made in later quarters. With all that said, I'll now hand the call over to Liam for his remarks.

Liam Kelly

executive
#2

Thanks, Larry, and good morning to all of you. It's genuinely a pleasure to be speaking with you today. For the fourth quarter, Teleflex delivered 7.9% constant currency revenue growth compared to a year earlier and a 10.4% increase over the equivalent period in 2019. During the quarter, we had one additional shipping day, which contributed roughly 1% to the year-over-year growth rate. Adjusted earnings per share climbed 10.8% versus the prior year. Our Q4 results reflected the company's balanced set of growth drivers, our wide-ranging portfolio of medically necessary products, and category leadership, partly offset by COVID-19's impact and the divestiture of the respiratory assets. As we had expected when we reported Q3 earnings, COVID-19 continued to act as a headwind in Q4, and elective surgical procedures did not come back to 2019 comparables. To be specific, COVID cases rose sharply during December in heavily populated geographies, such as the Northeast, Florida, Texas, and California. As COVID spread rapidly across those regions, we also observed growing staffing shortages as infections accelerated quickly late in the quarter. Teleflex performed well in the quarter, maintaining dependable service levels for our customers while navigating supply chain challenges, freight logistics delays, and reacting as COVID infection rates started to climb. Notably, if you exclude UroLift, the product hit hardest by the pandemic, revenue from the rest of the business rose more than 9% on a constant currency basis in Q4 versus a year earlier. Now to our 2021 performance. Even though the year brought difficulties, I'm proud to report that Teleflex executed extremely well. We met the unprecedented market disruption directly as the pandemic kept ebbing and flowing. We stayed diligent and flexible so we could support customer needs and keep our workforce safe. We responded effectively as freight and raw material supply issues intensified over the year. All year long, we held to our objectives by pushing forward our strategy of generating durable growth, expanding margins, and being good stewards of our balance sheet. Over the year, we invested in our growth drivers, executed our overseas strategy, and launched new products. Our customers stayed at the center of what we do, and Teleflex team members made it possible for us to supply customers with the products needed to care for their patients. We kept optimizing our portfolio through the integration of the HPC and Z-Medica acquisitions, and we divested certain low-growth and low-margin respiratory assets. We also kept our attention on our people as we strengthened our culture and moved our ESG initiatives forward. Financially, we met our full year 2021 commitments, with constant currency sales growth of 8.8%. Adjusted operating margin expansion of 310 basis points and adjusted earnings per share of $13.33, up 24.9% year over year. None of this could have happened without the tireless efforts of the global Teleflex team. I want to thank our employees for their hard work and dedication during 2021 and throughout the pandemic. Now let's take a closer look at the revenue numbers for Q4. First, I'll walk through what we reported for each of our segments. Unless I say otherwise, every growth figure I mention reflects constant currency. In Q4, our Americas, EMEA, Asia, and OEM segments all proved resilient — each region posted constant currency revenue growth over 2020 once you set aside the extra shipping day, and that's in spite of the ongoing COVID-19 headwinds. As I noted before, this really highlights what our diversified product portfolio brings us. In the Americas, revenue came in at $451.7 million for Q4, a 7.6% increase year-over-year. The year-over-year gain was driven by surgical, vascular, and interventional, though COVID-19 partly offset that. EMEA brought in $164.5 million, up 4.8% year-over-year, led by interventional, surgical, and vascular access products. EMEA is still dealing with a COVID-19 headwind, even though procedure volumes improved year-over-year as countries throughout the region kept reopening. If you exclude the respiratory divestiture, revenue was up 8.7%. Now to Asia. Revenue reached $78.5 million, up 0.5% year-over-year. Backing out the respiratory divestiture, revenue climbed 6.7%. Let's shift to Q4 revenue by global product category. Just like with my earlier segment comments, I'll discuss global product category growth in constant currency and in order of the size of our business units. Starting with vascular access. Q4 revenue rose 6.4% to $193 million. Because we lead the category in central venous catheters and midlines, and thanks to our novel coated PICC portfolio, we remain positioned for dependable growth. The PICC portfolio keeps performing well, growing 11% year-over-year, as we keep investing behind our differentiated portfolio and picking up market share. Intraosseous remains a dependable growth driver, with Q4 revenue up roughly 17% year-over-year. Now on to interventional. Q4 revenue was $114.9 million, an 8.2% increase year-over-year. Demand was strong for our complex catheters and balloon pumps; we continue to invest behind our interventional portfolio, which includes complex catheters and the MANTA device. MANTA's momentum is still strong in both the U.S. and international markets, growing approximately 45% year-over-year. Notably, we beat our goal of 8% share in 2021 of the $200 million-$300 million global market opportunity. Next, anesthesia and emergency medicine. Q4 revenue was $102.8 million, up 20.5% year-over-year. Interventional powered the quarter's growth, offset by difficult comparisons in the airway business and weaker tracheostomy sales. Hemostat revenue was roughly $66.5 million, landing in the $60 million-$70 million range we had set entering 2021; in our surgical business, revenue was $106.4 million in Q4, which represents 16.1% growth year-over-year. Within our largest product categories, we kept seeing robust growth in sales of our instruments and ligation clips, since the elective surgical procedure environment was stronger than the same period a year ago and hospital capital spending rose. Turning to interventional urology, fourth-quarter revenue came in at $92.9 million, which was down 1% from the prior-year period and up 12% on a sequential basis. That figure topped the implied guidance range of $85 million to $91 million for the quarter. We observed a definite uptick in UroLift procedure trends across October and November relative to the third quarter. That said, December took a year-over-year hit from the COVID-19 surge, along with ongoing staffing shortages and a rise in procedure cancellations. Notably, we saw no pull forward of UroLift procedures into the third quarter of 2021 from 2022 stemming from the November announcement of the Medicare physician fee schedule final rule. OEM revenues climbed 13.9% year-over-year to $67.2 million in the fourth quarter, with customer demand staying robust across our portfolio. We continue to be well-positioned thanks to broad capabilities in our markets, among them faster growth opportunities in thin-walled, advanced interventional micro catheters used in neurovascular and other applications. Lastly, our other category, which incorporates sales of respiratory products not included in the divestiture to Medline, urology care and manufacturing and supply transition agreement revenues, fell 12.2% to $84.7 million year over year. That decline reflects revenues lost from the respiratory products divestiture, partly offset by manufacturing and supply transition agreement revenues and growth in urology care.

Liam Kelly

executive
#3

We still anticipate that revenues from the manufacturing and supply transition agreement will taper off by the close of 2023. That wraps up what I had to say regarding Q4 revenue performance. Now let me move to a few commercial updates, beginning with UroLift. When we look back at 2021, COVID-19 remains the single most disruptive factor affecting the interventional urology business. Because BPH treatments can be deferred, patient willingness may fluctuate based on how severe the pandemic is. Here's what we've seen: UroLift procedure volumes drop when COVID cases go up, then recover after infection counts come down. Beyond that, the staffing shortfalls we called out in Q2 disrupted the business, particularly at our office site of service. A key point is that our analysis continues to show no share loss to rival device-based BPH treatments. UroLift revenues rose 18% year-over-year during 2021, despite the fact that urology procedures as a whole remained under pre-pandemic levels. We continue to believe UroLift is set for accelerating growth once pandemic pressures ease. During the early part of Q1, COVID continued to act as a headwind, though we anticipate that sales trends will strengthen as the year progresses and elective surgical procedures face fewer disruptions. When compared with other outpatient BPH treatments, UroLift stays differentiated thanks to robust clinical results, research demonstrating quick symptom relief and recovery, an absence of new sustained sexual dysfunction, and durable outcomes. Those who invest in Teleflex and follow the company know that UroLift is aimed at patients dealing with BPH who have either failed drug therapy or are dissatisfied with it. In 2022, we will deliberately place intense focus on boosting utilization among current UroLift users and increasing the productivity of surgeons whose training occurred during the pandemic. We're going to get our sales force completely behind the UroLift 2 launch as well, and we expect that nearly all U.S. users will have made the switch by the time 2022 wraps up. UroLift 2 is still a key contributor to our margins, and once the entire U.S. user base has converted, we continue to expect 400 basis points of gross margin expansion from UroLift. Our thinking is that taking a tactical approach to bringing current UroLift users back to the procedure volumes they had before the pandemic is the most efficient route to stronger growth in 2022. Turning to consumer marketing, we still see direct-to-consumer efforts as a multiyear catalyst for UroLift here in the U.S. When it came to 2021, every one of the goals we set internally for the DTC campaign was surpassed, and I'd like to walk through a few standout points. Impressions rose by close to 200% compared with the prior year, beating the 150% target we had set. In the same way, awareness of the UroLift brand climbed 60% versus a year earlier, reaching 16%, and it has now moved ahead of TURP, which sat at 14% and fell 600 basis points during 2021. It's worth noting that our DTC efforts are tightly aimed at generating revenue for Teleflex, because the overwhelming majority of the customers we serve provide UroLift as the only minimally invasive option for treating BPH. We intend to keep funding the DTC campaign through 2022 while preserving our ability to scale it up or down as the macro environment dictates. Beyond all of that, growth achieved in markets beyond the U.S. is still moving forward, and we anticipate a number of milestones during 2022. In Japan, we're making steady headway toward a commercial launch of UroLift that's coming up. Reimbursement for UroLift was secured this past December, and our team is ready to kick off the rollout launch as soon as that reimbursement takes effect on April 1 of this year. For UroLift, Japan stays a significant long-term possibility, carrying a $2 billion TAM, and we're eager about the launch ahead. Our expectation continues to be that sales in this region will build up much like they did in the U.S., within a market that's one-third the size. Switching over to Brazil, our early commercial efforts have us feeling optimistic, with attention on training surgeons and locking in reimbursement over the next few years. More UroLift launches may arrive in the back half of 2022, among them France plus initial work in Italy and Spain. And last, we're still on schedule to obtain regulatory clearance in China during 2023. To wrap up the UroLift update, on December 10, 2021, President Biden put his signature on the Protecting Medicare and American Farmers from Sequester Cuts Act, making it law. Among the many notable components of this bill, it boosted the Medicare physician fee schedule conversion factor by 3% for 2022 versus the November final rule; specifically for UroLift, that change translates into an additional $100-$150 in office-based profitability for 2022 relative to the MPFS final rule. We take encouragement from this reimbursement gain, and we will continue working alongside stakeholders to address the unintended effect of the physician fee schedule modifications, which will narrow choices for Medicare beneficiaries and steer procedures toward higher-cost sites of service. Turning now to a few updates in our Interventional business unit. We've wrapped up growing our sales team. The reason we did that is to give MANTA training more support and push deeper into the market. Over on the clinical front, we recently secured 510K clearance. That lets us expand what our specialty support catheters, guide extension catheters, and specialty guide wires are indicated for, so now they include cross-chronic total occlusion. Our submission to the FDA was based on positive results from a peer-reviewed, prospective, single-arm IDE study. That study enrolled 150 patients across 13 investigational centers in the United States. The study hit its protocol's primary endpoint for procedural success, and it also reached technical success — successful guide wire recanalization happened in more than 93% of these highly complex CTO cases. When it comes to interventional cardiology, we see complex PCI — especially CTO PCI — as a space where growth is strong. The new indication we've just received keeps us in a solid competitive position. Last, we continue to drive innovation on the MANTA core platform, and during the quarter we began a limited market release of the 14 French depth locator. This depth locator expands how the 14 French MANTA closure can be used with Impella in emergent cardiogenic shock procedures. Turning to QuikClot, we got a completed response letter, but U.S. regulatory clearance still hasn't been granted. The key point is that we don't need to collect any more clinical data, and it's clear to us precisely which additional items the FDA is requesting. Securing the FDA's green light for this novel, innovative product is still what we're aiming for, and we'll work alongside the agencies; as soon as we have further details that can be shared, we'll update the investment community. Now let's turn to Omicron and its effects. A lack of healthcare providers is still with us. Our expectation is that the impact in 2022 will be less than what we saw in 2021. We believe elective surgical procedures should improve in 2022 compared with 2021. Healthcare systems around the world are making impressive progress in their ability to adapt to the pandemic environment. With COVID cases spiking repeatedly, hospitals continue to improve their handling of COVID-19 patients even as they perform elective surgeries; in the same way, we expect a growing number of people to complete their vaccinations and treatments for the virus after someone becomes infected to be more and more accessible. Our guidance range takes into account various possibilities regarding COVID's effects, and the degree of disruption in those possibilities determines how we view the high and low ends of our forecast. In addition, our 2022 guidance assumes that operating expense will return to normal levels once the pandemic's influence diminishes.

Liam Kelly

executive
#4

We're going to keep funding our commercial team so they stay in front of customers, and we'll keep putting money into the things driving our growth. Managing Teleflex for durable growth over the long term matters, and we'll carry on funding those investments so we stay well-positioned. That said, if COVID disrupts revenues more than we've assumed, we'll be able to modulate spending while still funding long-term growth projects. Putting all of that together, for 2022 we'd expect underlying constant currency growth that captures our prior 2019 to 2021 LRP growth algorithm of 6%-7%, after adjusting for the 1.6% headwind from the divestiture of the respiratory assets. Over the past several years we've made substantial progress reshaping the Teleflex portfolio, investing behind growth drivers and divesting slower growth respiratory assets. Looking ahead, if you exclude UroLift and our other business, the remaining three-quarters of our business is positioned to grow 4%-5%. That growth is propelled by a base of medically necessary products plus our high-growth portfolio, including MANTA, Hemostat, Intraosseous, and PICCs. On top of these revenues, UroLift remains a significant opportunity as pandemic-related disruptions recede in the United States, and we execute on our multi-year, multi-geography overseas expansion. We'll also continue to execute on our M&A strategy to layer in additional growth drivers. That completes my prepared remarks; now I'd like to turn the call over to Tom for a more detailed review of our fourth quarter financial results. Tom?

Thomas Powell

executive
#5

Thank you, Liam, and good morning everyone. Since we already went over how the company performed on revenue, I'll start with margins instead. In the fourth quarter, both gross and operating margins stayed robust and came in above what we saw in the same period of 2020. Thanks to the strides we keep making on expanding margins throughout 2021, we've been able to put more money into the areas that drive growth, which matters a great deal to our longer-term plan for building durable growth. Adjusted gross margin for the quarter came to 58.8%, which is 80 basis points higher than the same period a year ago. That year-over-year gain in gross margin came from product and regional mix, benefits from restructuring, programs aimed at operational efficiency, favorable pricing effects, M&A, and foreign exchange — though these were partly offset by inflation in freight, raw materials, and labor. Adjusted operating margin for the fourth quarter reached 27.6%, up 100 basis points from a year earlier, helped by the gross margin gain along with disciplined expense management, and partly offset by planned investment in the business plus a partial normalization of expenses after we made deep cuts to discretionary spending in the prior year because of the COVID pandemic. Net interest expense came to $11.8 million in the fourth quarter, down from $18.5 million in the same period a year ago. That year-over-year drop in net interest shows the savings from redeeming the 2026 senior notes early, along with the effect of paying down outstanding debt using proceeds from the respiratory divestiture and cash flows from operations. Our adjusted tax rate for the fourth quarter of 2021 was 13.8%, versus 10.1% in the same period a year ago. The year-over-year rise in our adjusted tax rate is mainly because the benefit from stock-based compensation was lower than in the prior year period. On the bottom line, adjusted earnings per share for the fourth quarter rose 10.8% to $3.60 and came in ahead of what we had expected internally. Now turning to a few balance sheet and cash flow highlights. Cash flow from operations for 2021 came to $652.1 million, compared with $437.1 million in 2020. That's a year-over-year increase of roughly $215 million. The gain was mainly due to favorable operating results, lower contingent consideration payments, and proceeds from the respiratory business divestiture that were tied to performance obligations under the manufacturing and supply transition agreement. Moving to the balance sheet. Our financial position is still solid. At the close of Q4 2021, our cash balance stood at $445.1 million, versus $375.9 million at the close of Q4 of 2020. During Q4, we paid back $200.5 million of borrowings under our revolving credit facility. At the close of Q4, $141 million remained outstanding on our revolver. Net leverage at quarter end was about 1.7 x, which is still comfortably under our 4.5 x covenant. And finally, we have no debt maturities of material size in 2022 or 2023; now let's move on to our 2022 guidance. To start, I'll lay out a framework of the key planning assumptions that underpin our financial guidance. While it's tough to forecast given where things stand right now, when we look at 2022 we're working from an assumption that elective surgeries will be better than they were in 2021, while still building in some COVID-related disruption during the first quarter. On top of that, we anticipate that inflation will run hotter in 2022 than it did in 2021, and that the pressure will be heavier during the first half than in the second half. The guidance ranges we're giving for 2022 take into account the uncertainty around how severe COVID will be, what staffing shortages will do, and inflationary pressure. At the upper end of the range, we're assuming these factors have less of an effect, though the environment still wouldn't be completely normal; beyond that, our planning assumptions leave out any significant regulatory or healthcare reform, and they also leave out any future M&A that hasn't been disclosed. So now let's go through the main pieces of our 2022 guidance, beginning with revenue. We feel good about both our portfolio of high-growth drivers and our durable growth core. Given the near-term pressure we expect from the recent COVID surge, we're starting the year with a measured approach. For 2022, we're expecting constant currency revenue growth of 4%-5.5%. If you set aside the 1.6% headwind tied to last year's sale of the respiratory assets, that puts expected constant currency revenue growth at 5.6%-7.1%, which reflects the growth algorithm we laid out previously in the 2019 to 2021 LRP. Our high-growth portfolio spans a number of business units and includes UroLift, MANTA, Hemostats, EZ-IO, LMA, and PICCs, and it made up roughly 25% of total revenues in 2021. As our 2022 constant currency revenue guidance implies, we expect this high-growth portfolio to grow in the mid-teens, with UroLift increasing by about 15%. For our durable core platforms, which represent more than 60% of revenues, we're estimating growth of roughly 4%. Our other category covers sales of respiratory products that weren't part of the divestiture to Medline, revenues from the manufacturing supply transition agreement, and urology care, and that category represented approximately 12% of total revenues in 2021. Looking at 2022, we expect this segment to be down in the low to mid-teens compared with last year, mainly because of the respiratory divestiture. Let's shift now to currency. We're expecting foreign exchange rates to act as a roughly 1.7% headwind to revenue growth. That means reported revenue growth should come in at 2.3%-3.8% versus last year, which works out to a range of $2.874 billion-$2.917 billion. Turning to gross margin, we're expecting adjusted gross margin in the range of 59.75%-60.25%. We keep getting a lift from mix shift toward higher margin products, from restructuring, and from operational efficiencies, though incremental inflation offsets part of that. We estimate that incremental inflation will be a headwind of about 70 basis points in 2022, driven mostly by higher freight costs, raw materials, and direct labor. Our guidance bakes in an assumption that those elevated freight costs will get better during the second half of the year. As for operating margin, we're expecting adjusted operating margin in the range of 27.75%-28.25%. Our 2022 guidance assumes that incremental investments will back our key growth drivers, among them UroLift, MANTA, intraosseous, and the Asia Pacific region. Also, as we said before, we still anticipate that operating expenses will normalize once COVID-related disruptions ease. Remember that in 2020, because of how the pandemic affected revenues and commercial activities, discretionary operating expenses—such as T&E and open headcount—were cut back considerably. Even though operating expenses rose in 2021, they had not yet returned completely to pre-COVID levels. In planning for a better environment in 2022, we are assuming both a normalization of our operating expenses and investments in our growth drivers. Even with the disruptions of the past two years, we keep making substantial progress on our margin expansion initiatives. Notably, comparing the midpoint of the 2022 guidance with 2019 pre-pandemic levels shows a healthy 190 basis point increase in gross margin and a 220 basis point increase in operating margin. We believe our incremental investment is prudent to fuel our long-term durable growth initiatives, particularly as we see the disruption from the current COVID surge improving over time. In turn, we view 2022 as a transition year for margins, since multiple levers remain to drive profitability higher over the coming years, including product mix shift, manufacturing efficiencies, and announced restructurings, partially offset by continued investments in the business to sustain our durable growth profile. Moving down the P&L. We expect net interest expense to be approximately $51 million.

Thomas Powell

executive
#6

The drop in interest expense compared with a year earlier mostly comes from paying down debt, which we did using money from selling the respiratory business along with robust cash generation. Now on to taxes. For 2022, we expect our adjusted tax rate to fall somewhere between 10.5% and 12.5%. One thing worth noting: the top of that range takes into account a shift in how certain R&D expenses can be deducted for tax purposes starting in 2022, under the 2017 Tax Cuts and Jobs Act. Our understanding is that lawmakers on both sides back these R&D tax benefits, so it's possible the rules that took effect for 2022 get rolled back at some point this year. Should that repeal happen, we'd expect our tax rate to land nearer the bottom of the guided range. Taking all of this into account, our adjusted earnings per share outlook for 2022 sits at $13.70-$14.30, which works out to a 2.8%-7.3% rise versus last year. Built into that guidance is a headwind of roughly $0.17 tied to the respiratory business we divested, plus about $0.33 from added inflation. If you set aside the respiratory divestiture and the extra inflation, earnings per share growth should come in around 7%-11%. Keep in mind that the bottom of our adjusted EPS growth range is where the R&D deductibility tax change shows up. For the full year 2022, we project weighted average shares outstanding will rise to $ 47.7 million. Finally, I'd like to give a bit more detail on how our 2022 financial results will be paced, in particular three things that will affect our first quarter numbers. First, as I noted earlier, we expect continued COVID-related pressure on elective surgical procedures to weigh on our first quarter results, much like what a lot of medical device companies are seeing so far. Second, keep in mind that Q1 has one fewer selling day than the comparable stretch of 2021. Third, the foreign exchange headwind should be bigger in the first quarter and Q2, then ease up during the back half of 2022. With that, we expect reported revenue to be roughly flat versus a year ago in the Q1 . On a constant currency basis adjusted for days, ourQ1 growth should come in around 3%-3.5%. Leaving out the respiratory divestiture's impact, our days adjusted constant currency growth should be about 5.5%-6% in the first quarter; we also anticipate adjusted gross and operating margin will be down versus a year earlier in the first quarter, due to added inflation and operating expenses returning to normal levels. That wraps up my prepared remarks. I'd like to hand things back to Liam now for closing commentary. Liam?

Liam Kelly

executive
#7

Thank you, Tom. To wrap up, I'd like to walk through the three main points from the quarter along with what we expect for 2022. To begin with, because our product portfolio is diversified, Teleflex was able to achieve constant currency growth of 7.9% during the fourth quarter and 8.8% across 2021, even with the considerable COVID-related disruption we faced throughout the year. Next, we keep carrying out our strategy aimed at generating durable growth throughout that diversified portfolio, through investment in organic growth opportunities, expansion of margins, and deployment of capital toward M&A. And third, our confidence in that growth strategy remains strong; we expect our core growth platforms to deliver 4%-5% growth, with the rest of the growth coming from UroLift as pandemic headwinds subside. We have levers in place to drive further margin expansion, and with leverage at 1.7 x, our balance sheet sits in a solid position, giving us ample financial flexibility for our capital allocation priorities. Our confidence in the future, and in our ability to keep meeting our commitments to patients, clinicians, communities, and shareholders, remains strong. That brings my prepared remarks to a close. At this point I'd like to hand the call back to the operator for Q&A.

Jayson Bedford

analyst
#8

Morning, and I appreciate you fielding these and giving us such a thorough rundown. To kick things off, I don't want to get too deep in the weeds, but could you perhaps share what the current landscape looks like compared with, say, 1 month back? I'm simply hoping to hear something reassuring — that things are starting to tick up a bit now that COVID is fading.

Liam Kelly

executive
#9

Sure. Throughout every part of our operations, Jayson, it's clear that whenever a COVID flare-up happens, some areas gain and some lose. Certain segments perform better, others perform worse. Vascular, clearly, along with a few of our respiratory filters, perform better. When it comes to elective procedures, UroLift leads that group, and after that surgical and interventional generally perform worse. Looking at how things unfolded as we reached the close of August and that most recent surge, we noticed UroLift procedures in particular climbing during September, October, and November, after which they took a hit in December, and that carried over into January; our expectation is that things will get better once hospitals start reopening and once patients feel more at ease about coming in for these procedures. We foresee conditions getting better during February and during March. Once again, I have to give credit to hospitals, physicians' offices, and ASCs. They're handling these fresh surges far more effectively. The problem with Omicron was its much greater transmissibility, which meant it genuinely worsened the staffing crunch, since people had to quarantine for 5 days after exposure purely because of how infectious it was. So yes, conditions improved as we moved through February, Jayson, which directly answers what you asked.

Jayson Bedford

analyst
#10

All right. As a brief high-level follow-up question. Liam, in the release you mentioned optimizing the portfolio for growth, which aligns with what you've said before. So the question is whether the present climate is more or less favorable for your approach? Put differently, is there room for you to be more active right now?

Liam Kelly

executive
#11

Well, Jayson, the single thing required to be active is firepower, and plenty of firepower is what we have. As mentioned during the call, our leverage stands at 1.7 x, so firepower is there. Here's another way to put it. Regarding valuations, my feeling today is far better than 12 months ago. Our portfolio is always being augmented. Keep in mind that over the past 24 months, HPC and Z-Medica were acquired by us, and our respiratory assets were divested. Out there, we are active. Assets are being pursued by us. As the IPO market has shifted, valuation expectations have shifted, I believe. It isn't only us conveying that to the private companies — the banking community is also communicating it to them. Yes, I'm pleased that our financial discipline was maintained throughout the last 12 months when things were pretty heady out there. Conversations with private companies are now a lot easier, I think, and at this stage, compared to an IPO, they view a strategic exit as very, very favorable.

Larry Biegelsen

analyst
#12

Hello, and good morning. I appreciate you taking my question, and congratulations on a strong finish to the year. Liam, I'd like to begin with UroLift. What are you observing regarding the reimbursement change that happened recently? From a broader perspective, regarding the contribution to growth, you mentioned — I believe — a range of 4% to 5%, with UroLift serving as a bridge toward your long-term objective, which I think is 6%-7%. How much growth, and where do you expect that incremental growth to originate? What portion comes from international markets, and what other factors are driving it? I have one follow-up question.

Liam Kelly

executive
#13

Yes, Larry. Regarding UroLift, to begin with, we're extremely happy with how strongly we closed out the year — $93 million during the fourth quarter. In fact, our performance across the entire year, and I appreciate you recognizing that, is something we take real pride in; we achieved revenue growth of 8.8% compared with our initial guidance of 8%-9.5%. Keep in mind that the initial guidance included $28 million-$32 million in respiratory revenue that we divested. We achieved gross margins of 59.4, which is 270 basis points of expansion, and op margin with 310 basis points of expansion. On earnings per share, we saw 25% growth in earnings per share, all while losing $0.10-$0.15 from the respiratory divestiture. Going forward, we've clearly stated that we anticipate UroLift growing 15% this year. We believe that is very achievable given the current environment. We expect COVID to have an impact during the first quarter, as anyone would expect; after that, we'd anticipate lower single digits during the first half of the year, followed by a strong pickup in the back half. Clearly, Q3 has an easier comp; then, as we move into Q4, with people working through their deductibles, you'd expect that trend to persist. We have real confidence that our core business is well positioned for 4%-5%, Larry; assuming good execution, I believe we ought to land at the upper end of that range. Our growth algorithm of 6%-7% remains very much intact, as our guidance today demonstrates. Our constant currency guidance is 4%-5.5%, though there's a 1.6% headwind stemming from the respiratory divestiture. There's 30 basis points from the loss of a day, which falls in Q1, and that actually brings you to 5.9%-7.4%. If anything, the algorithm has gotten better thanks to the base, our core business performing even more strongly through good execution and genuine, solid investment behind some of our strong growth assets, including intraosseous, including our PIC portfolio, including MANTA, and including our hemostatic portfolio.

Larry Biegelsen

analyst
#14

That's useful. For my follow-up, Liam, building on what Jayson asked before regarding M&A, what do you look for? Like, how do you consider deal size, and are there any particular areas that interest you that you could mention? Thanks for taking the questions.

Liam Kelly

executive
#15

Sure thing, Larry. We target businesses generating between $60 million and $300 million in revenue. Our strategic lens is that the asset aligns with one of our pillars or sits in a neighboring space; it holds very strong IP, offers an excellent value proposition inside the hospital, and delivers better clinical results than whatever else is on the market; we favor products with stickiness, ones that see repeated use. Naturally, we seek assets that add to our gross margin, and we seek assets that will eventually add to our op margin. We're willing to tolerate some near-term op margin dilution, as we did, for instance, with NeoTract, provided we can foresee leverage down the road. Those really are our financial and strategic criteria, Larry, and I appreciate the questions.

Matt Taylor

analyst
#16

Hi there, and thanks for fielding this. Morning to you.

Liam Kelly

executive
#17

Morning, Matt. Morning.

Matt Taylor

analyst
#18

Morning. I'd like to zero in on UroLift and that 15% steer, with a couple of questions. First, can you give us more granularity on how UroLift's expansion should be paced across the year? And what size of a boost do you expect Japan to deliver?

Liam Kelly

executive
#19

Sure, fair question, Matt. Like I told Larry, the opening six months will see growth in the lower single digits, reflecting COVID-19's effect during Q1 and, clearly, not enough staff. Meanwhile, the back half of the year should post genuinely robust double-digit expansion. International markets will add only a little. Japan, Brazil and France are in the mix; their ramp comes in the latter half of the year, yet they won't turn into anything material, Matt, before 2023 and past that. So across 2022, the U.S. remains the primary engine behind UroLift's growth. Let me tack on one more point, Matt, which I raised during my prepared remarks: we kept training right through the pandemic. That's the single strongest tactical lever for pushing UroLift growth during 2022, after which the overseas markets come into play in 2023 and later. Per what Tom laid out in his prepared remarks, 25% of our overall revenue sits in that mid-teens growth bucket, and UroLift is part of it. On top of that, MANTA, Hemostat, Intraosseous and PICCs are each fueling that genuinely sturdy top line expansion at Teleflex.

Matt Taylor

analyst
#20

Thanks, Liam. To pick up where we left off regarding the pipeline, did you provide any news on Reclast EasyClad, or might you share an update about where things stand with it?

Liam Kelly

executive
#21

Yes, Matt, that was covered in my prepared remarks. During those remarks, I mentioned that a CRL has come through, and right now we're addressing the information that was asked for. The encouraging part is that what the FDA wants isn't centered on clinical data, and we have a clear view of the extra information the agency is seeking; we'll keep engaging with the FDA, and the process has been highly collaborative. Matt, we can see this clearly: it's also the first instance of the FDA giving the green light to a biologic product of this kind, so together we're venturing into uncharted territory. Matt, as you know—and as most investors will know—the military's RFP falls inside that $3 million to $4 million range. Sure, it's a promising market down the road. We'll expand into a $100 million opportunity, but our guidance for this year does not include that $3 million-$4 million.

Matt Taylor

analyst
#22

Great. Thanks, Liam.

Liam Kelly

executive
#23

Cheers.

Shagun Singh

analyst
#24

Thanks. Appreciate you fielding this. I wanted to ask whether you could share how inflation and FX are affecting margins and EPS in Q4. What assumptions went into 2022? On margins specifically, could you walk us through the bridge from 2021 to 2022? I'm trying to get a handle on the puts and takes. So regarding, I suppose, the UroLift 2 conversion, we have a bit under 40 basis points from inflation. On the call, I believe you mentioned 70 basis points. Annual pre-tax savings — I think there's roughly $40 million across 2022 and 2023 — plus a greater amount of investment. A bridge would really help.

Liam Kelly

executive
#25

Thanks, Shagun; that kind of granularity calls for someone named Thomas Powell. Tom.

Thomas Powell

executive
#26

All right. Regarding the first question, it concerned how inflation and foreign exchange affected the fourth quarter. When examining Q4, I'll address FX initially. We observed a slight shift in exchange rates. The tailwind we'd enjoyed during the earlier portion of the year diminished considerably. Versus the previous year, it hurt our margins, yet on a year-over-year comparison it remained marginally favorable. On inflation, we had mentioned it rising in Q4 compared with what we saw in Q3, and we'd projected the figure at roughly $3 million; in reality it came in greater, near $4.5 million, during the fourth quarter. Clearly, we've presumed this will keep being somewhat the situation as we head into the coming year. When considering margins as we enter next year, there are various positive and negative factors. To begin, regarding gross margin, I want to remind everybody that it rose 270 basis points in 2021 compared with 2020. That's genuinely robust expansion in 2021 even with a more inflationary backdrop. Looking toward 2022, our guidance stands at 59.75%-60.25%, which means a 60 basis point rise at the midpoint. This gross margin gain stems, as noted, mainly from mix—largely UroLift—plus restructuring and operational efficiency programs, partially offset by inflation. For 2022, our guidance presumes supply chain inflation runs about $20 million above the 2021 inflation level, translating to an incremental inflation effect of roughly 70 basis points. If you examined our gross margin guide without that incremental inflation effect, we'd be up around 130 basis points at the midpoint. Thinking about the cadence of gross margin, we do anticipate a strengthening gross margin throughout 2022. At present, our guidance incorporates an assumption that we'll experience some easing in raw material and logistics inflation during the second half of the year compared with the levels we now expect. We also anticipate a mix benefit as the year progresses, since UroLift will make up a larger share of the mix while the manufacturing supply agreement becomes a smaller share. Broadly speaking, gross margin is affected by inflation, and the cadence of quarterly margin expansion is affected by both inflation levels and mix; now, turning to operating margin, we are guiding to 27.75%-30.25%. That's flat versus 2021 at the midpoint. A few points, once more, to emphasize. To start with, that rise in supply chain inflation does hurt gross margin — and it flows through, bringing down operating margin as well. Next, I want to point out that back in 2020, our OPEX spending came down considerably because of the COVID pandemic — partly since the pandemic restricted what we could do commercially, and partly since we aimed to cut costs so we could counter the revenue effects of COVID; then in 2021, we brought back some of those activities and some of that spending, though neither activity nor spend returned to where it stood before the pandemic. For 2022, our guidance bakes in a broad return to normal commercial activity, such as hiring, sales, training, meetings, and so on. Because of that, we'll take on roughly $20 million, or 70 basis points, of extra OPEX during the year. Looking at op margin, if you set aside the supply chain inflation effects and the expense normalization, we would find an improvement of about 140 basis points at the midpoint. Beyond that, during 2022 we intend to keep putting money behind our key growth franchises, which include UroLift, MANTA, and EZ-IO. Given how well things have gone with UroLift DTC and with the sales force additions, I'd say we'll keep investing in that area and behind MANTA; and then, well, I... As you know, we will see op margin get somewhat better as the year goes on, for many of the same reasons we've been discussing when it comes to gross margin improvement. I hope that covers it.

Shagun Singh

analyst
#27

Understood. I really appreciate the extra detail.

Liam Kelly

executive
#28

Right. I hope I managed to address everything you asked.

Shagun Singh

analyst
#29

Yep. Appreciate it.

Liam Kelly

executive
#30

Thanks, Shagun.

Cecilia Furlong

analyst
#31

Thanks, and good morning. I appreciate you taking my questions. Liam, I'd like to begin with the topic of driving adoption among physicians who've recently completed their training. Could you describe the main priorities you have for this year? And then perhaps the broader, longer-range vision. Once COVID is behind us, and considering that international markets such as Japan, China, Brazil, and Europe are beginning to come online, how do you view the sustainable, long-term growth trajectory for your UroLift?

Liam Kelly

executive
#32

Regarding the second part of what you asked, Cecilia, one thing that's very evident to me is that once we're past this period, UroLift will grow quite substantially. So of course, when December came around, things slowed down as a result of the COVID outbreak. Even so, we ended up doing better than what we'd set internally, thanks to how strongly things grew during the first two months of that quarter. Cecilia, the reason we're centering on just a handful of growth pillars for UroLift comes down to this. Driving utilization among doctors who already use it will serve as our first pillar over the coming years. During COVID, what stood out to us was our champions and our interventionists. Keep in mind, these are folks who, at a very, very high rate, offer nothing but UroLift. Due to patients holding back and not enough staff on hand, their usage has slipped somewhat during the COVID period. Getting UroLift back on track to produce that 15% growth is most easily done by boosting utilization in that area. The second thing, looking ahead, is to keep doing that while also pushing into markets abroad. Japan will start showing up beginning April first. France will appear during the back half of the year. Brazil will keep gaining momentum as the year goes on. China will arrive next year, and perhaps somewhere like Taiwan after that. Italy and Spain will follow along. In most cases, a company can anticipate that its U.S. revenue level should be roughly matched by overseas revenue over a span of several years, provided execution abroad goes well. And then there's the final piece, which is clearly adding new physicians — throughout the year we'll keep training additional doctors. Everyone should understand, I believe, that this market remains far from fully penetrated, by any measure. Of the 12,000 docs out there, we've trained only around 3,400, and our procedure total stands at just 300,000 — nearly all performed inside the United States — compared with 12 million men in the U.S. and 100 million around the world. So when I look at what's possible across a multi-year horizon, I feel quite optimistic. Our goal is simply to move past COVID and then truly demonstrate the growth potential this product has.

Larry Biegelsen

analyst
#33

Cecilia, this is Larry. I just want to note that at our analyst meeting in May, we'll of course be giving a longer-term perspective on how we see UroLift performing.

Mike Matson

analyst
#34

Hello, and thanks for fielding my questions. I'd like to inquire about those reimbursement modifications for UroLift that took place. My understanding is they became effective when the year started. Could you perhaps describe what you're observing in that regard? Are physicians shifting where they perform the procedure, or is anything else changing? Regarding that 15% guidance figure, how much, if any, allowance have you built in for this matter?

Liam Kelly

executive
#35

No change in site of service has appeared, and I don't expect any such change to emerge over the next year. The legislation President Biden signed actually raised reimbursement for UroLift when done as an office procedure by adjusting the conversion factor roughly 3%; that contributed an additional $100-$150 net to the urologist per procedure. On top of that, we've rolled out our own pricing approach in the market, and the reception has been extraordinarily positive. Just 6 weeks in, a very large share of our customers have enrolled in our program. I really don't foresee much movement in where the service is delivered. Mike, also keep in mind that 70% of UroLift cases we handle occur outside the office setting. The CMS decision affected only Medicare and Medicaid patients in the office, which works out, if you calculate it, to roughly 20% of the total. Strategies are in place, the team is carrying them out, and that 15% growth figure assumes everything we currently know plus our understanding of how COVID will unfold as the year progresses.

Mike Matson

analyst
#36

All right, thank you. If I could just quickly squeeze in one for Tom. Is there some sort of EPS effect coming from currency? I didn't hear that mentioned while you sort of went through the headwinds, but since it's meaningful to the top line, I wanted to check whether it was being offset on the bottom line. Thanks.

Thomas Powell

executive
#37

The currency effect we have baked into our guidance comes to roughly $0.20.

Liam Kelly

executive
#38

Hi there, Matt.

Matthew Mishan

analyst
#39

Morning. Is my audio coming through clearly?

Liam Kelly

executive
#40

You're coming through for us at this point.

Matthew Mishan

analyst
#41

All right, that's great. Hey, Liam, my first one is about vascular access; it keeps beating what we'd anticipated, and it sits roughly $100 million higher than the level from 2019. You appear fairly confident regarding PICCs and Vidacare as you sort of shift those into the high growth category. I'm simply wondering, how ought we to view how long that vascular access improvement lasts compared with certain other areas that might have benefited from COVID?

Liam Kelly

executive
#42

Yeah. When it comes to vascular access in this year, our expectation is mid-single digit expansion overall. Clearly, COVID helped our CVC portfolio across the past couple of years. The expansion actually stems from our intraosseous portfolio plus our PICC portfolio, since we keep gaining share thanks to our coating technology; for us this truly is a worldwide endeavor. We've brought out a genuinely impressive new CVC kit that's earning fantastic traction in the global marketplace, and that's additionally assisting us in uptrading customers on our CVCs across our key markets worldwide, though certainly in our key North American market; we feel genuinely positive; Matt, it's our biggest franchise. It keeps performing unbelievably well; we have a new... Alongside that new product, there's another new product arriving concerning our tip positioning and our PICCs that has us quite excited. You know, we've frequently stated that not all growth is equal. This ranks among the businesses receiving more R&D dollars than others and maintaining that flow, and new products arrive to keep us differentiated. It's a fantastic franchise.

Matthew Mishan

analyst
#43

All right, that's great. If I missed this, I apologize — could you give us an update on how Z-Medica wrapped up 2021, plus your thinking around what will drive growth for that product as we head into next year?

Liam Kelly

executive
#44

Sure. The way Z-Medica closed out the year makes us very pleased; we'd communicated to the investment community that it would land somewhere in the 60 to 70 range, and it came in right in that zone at $66.5 million. We take real pride in what was accomplished in folding that business into Teleflex. Our view hasn't shifted at all. With solid execution, that asset is more than capable of high single-digit, and possibly low double-digit, growth, and it's genuinely accretive to our margins. Once again, it's an additional growth driver, and it belongs in the category Tom mentioned that is averaging mid-teens% growth. Naturally, there's a cardiac study we wrapped up recently, and we'll be submitting to the FDA, which will also broaden the $600 million TAM, Matt. We're truly enthusiastic about that.

Dave Turkaly

analyst
#45

Great, thanks. Perhaps a few fast product questions in response to Matt. Regarding the PICC business, is there anything you'd mention about competition? You know, a larger competitor existed that expanded for years at the pace you appear to have currently. Has that situation shifted, or would you really cite the differentiated coatings as the way you're preserving that?

Liam Kelly

executive
#46

As far as we're concerned, coatings are everything. What shifted, Dave, is that previously, infection reporting on PICCs wasn't required of hospitals. The thinking was that while it wasn't being tracked, the belief was PICC infections were reduced. Infections on CVCs, or PICC, stood at 4% prior to our introducing coated technology for CVCs. We've managed to reduce it to essentially zero, as numerous studies indicate. Naturally, after PICC infection tracking began, what did they amount to? Approximately 4%; these days hospitals receive no reimbursement for such infections, which explains why our PICC technologies are performing so well. It truly centers on our coatings, which are anti-thrombogenic as well as anti-infectious.

Dave Turkaly

analyst
#47

Thanks for that. To build on something we rarely discuss — surgical — you brought up instruments and ligation clips, but 16% seems elevated, even accounting for procedures rebounding. So what's driving that, or what's different there? How can you post figures like that in a space I'd assume offers far less growth potential?

Liam Kelly

executive
#48

Yeah, well. Our surgical business is also a worldwide endeavor; we hold a very robust surgical presence across the Americas and APAC. As procedures recovered, our surgical portfolio recovered alongside them. We're also pursuing broader indications for our Weck ligation clips, which ought to assist us in sustaining that growth. That said, it won't expand at such a rate next year, and I don't want to give anyone the wrong impression that it will. It'll land in the low single digits throughout next year. We've got some fresh products in the pipeline arriving this year. Apologies — I meant next year. In this year, 2022, growth will be in the low single digits. There's a solid product pipeline flowing through, and we've broadened our vascular closure. We've genuinely put effort into our instruments. Naturally, our Weck's ligation clips keep delivering remarkably well worldwide. Honestly, the Surgical team has performed superbly in delivering results as procedures have come back.

Dave Turkaly

analyst
#49

Thanks.

Liam Kelly

executive
#50

Another thing we do is charge more. I ought to point out that this represents a good chance for us. I'll finish with pricing since I feel it matters that we left it out. We expect to have favorable pricing this year — that 50 basis points on systems we pushed through last year — to counter a portion of the cost pressures. Firms such as Teleflex, in my view, will come out ahead since we are accustomed to raising prices; it's baked into who we are, and we'll keep delivering on that pricing, especially with surgical inside our vascular business unit and also abroad in Asia and Europe. I simply wanted to state that before we wrap up. Thanks.

Lawrence Keusch

executive
#51

April, thanks very much, and thanks as well to all of you who are with us for today's call. That brings us to the end of the Teleflex Incorporated earnings conference call for the fourth quarter of 2021.

Operator

operator
#52

That brings today's conference to a close. We appreciate everyone for joining in. You are welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.